Around 700,000 Americans are estimated to live with brain cancer, and by the end of 2022, nearly 90,000 more will have been diagnosed with the deadly disease. In 2020, brain and Central Nervous System (CNS) tumors took more than 200,000 lives worldwide. It is a debilitating condition that can significantly reduce a patient and their family’s quality of life.
The most common treatment methods for brain cancer are surgery, chemotherapy and radiation. While these treatment options can allow people with brain tumors to live for years after they are diagnosed, they aren’t risk free.
Chemotherapy and radiation, for instance, cause side effects such as anemia, constipation, nausea, vomiting, hair loss, fatigue and infection, while brain cancer surgery can cause seizures, behavior or personality changes, dizzy spells, speech problems and confusion.
Looking to update brain cancer treatment protocols and make treatment more effective, the American Society of Clinical Oncology (ASCO) convened a panel consisting of a variety of medical professionals to re-evaluate existing brain cancer treatment guidelines, assess their effectiveness, and update them based on recent findings.
The panel included medical experts from oncology, radiation, neurosurgery and other medical fields who put their heads together to review recent scientific literature about brain cancer treatments. The ASCO put it together at the University of Virginia Cancer Center in 2020 and ran the panel for two full years, concluding the endeavor in 2022. Given the many individuals who brain cancer affects, making treatments more effective would benefit hundreds of thousands of people across the country.
David Schiff, a neurooncologist from the U.Va. Cancer Center who sat on the ASCO panel, notes the advancements brain cancer treatments have made over the past three decades. In the 1990s, he says, removing brain metastases surgically gained traction as it led to higher survival rates and improved patients’ quality of life.
Unfortunately, it also led to cognitive neurotoxicity as it would flood areas of the brain that were tumor-free with radiation, resulting in a reduction in brain function. Through the late 1990s and the early 2000s, a growing number of brain cancer treatment programs started including localized radiation.
The review showed that whole-brain radiation was frequently used in concert with other treatment options to reduce the risk to the patient. Targeted immunotherapy medications have also been found to offer some relief, especially in tumors caused by kidney cancer, lung cancer, or melanoma.. New guidelines now focus on growing treatment effectiveness while reducing toxicity, which spares patients from various side effects.
A number of companies, including CNS Pharmaceuticals Inc. (NASDAQ: CNSP), are also developing treatments that could be more effective without placing a heavy burden on patients with regards to the attendant side effects of those novel remedies.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Doctors in Spain recently handled a fascinating yet terrifying case of a patient that developed brain cancer-like symptoms and…
While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients…
Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production…
The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage…
As July came to an end, the United States reached an undesirable milestone: exceeding the…
Scientists and public health experts are warning that climate change is accelerating the rate at which infectious…